STAT1 and breast cancer: These data suggest that EPS may not utilize the canonical Interferon/JAK/STAT1 pathway to modulate breast cancer phenotypes as activation by interferon-γ did not induce cell cycle arrest and knocking down JAK1 did not interfere with EPS-mediated inhibition of proliferation.